Veeva Systems Trading Volume Surges 31.6% to 237th Rank as Shares Dip 1.95% Despite Strategic CRM Advances

On August 25, 2025, Veeva Systems (VEEV) traded with a volume of $370 million, a 31.6% increase from the previous day, ranking 237th in market activity. The stock closed down 1.95% despite recent strategic developments involving its Vault CRM platform.

Raymond James reaffirmed an Outperform rating for Veeva with a $310 price target, citing GSK’s large-scale deployment of Vault CRM across Europe. The implementation, completed on schedule and within budget, marks GSK—a $80.35 billion market cap pharma giant—as a top 20 pharmaceutical reference customer. The firm highlighted GSK’s prioritization of AI integration, a key differentiator in pharma CRM decisions, and noted Veeva’s competitive edge over Salesforce, which lacks a comparable live reference until 2029.

Separately, GSK reported Q2 2025 earnings of $1.24 per share, exceeding estimates by 5.08%, and revenue of $10.64 billion, surpassing forecasts. While these results reflect strong performance, no analyst actions were recorded for GSK in recent periods.

The strategy of buying the top 500 stocks by daily trading volume and holding for one day yielded a total profit of $2,940 from December 2021 to August 2025. The maximum drawdown was $1,960, with a Sharpe ratio of 1.53. December 2021 was the most profitable month ($840), while August 2025 recorded the largest loss of $790.